Ultra-small-volume gene editing system and application thereof in construction of cell factory

By developing an ultra-small volume gene editing system based on Campylobacter coli-derived TnpB protein, the problem of CRISPR-Cas9 system being too large in prokaryotes was solved, and efficient gene editing was achieved, especially in E. coli and mammalian cells. efficient editing ability.

CN118995669APending Publication Date: 2024-11-22ZHEJIANG UNIV OF TECH
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411397936.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing CRISPR-Cas9 gene editing system is too large in prokaryotes, which makes delivery difficult, and the streamlined version of the CRISPR-Cas system is not efficient and lacks efficient small-volume gene editing tools.

Method used

Developed an ultra-small gene editing system based on Campylobacter coli-derived TnpB protein (CcTnpB), including CcTnpB protein, ReRNA molecules and targeted guide sequences to form a complex for gene editing. The CcTnpB protein has only 277 amino acids and has a higher level of Vitality and editing efficiency.

Benefits of technology

It realizes efficient gene knockout, insertion and continuous editing in E. coli and mammalian cells, providing a simpler, more efficient and precise gene editing tool with higher cell delivery efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995669A_ABST
    Figure CN118995669A_ABST
Patent Text Reader

Abstract

The invention provides an ultra-small-volume gene editing system based on TnpB protein derived from Campylobacter coli and application of the ultra-small-volume gene editing system in construction of a cell factory. The ultra-small-volume gene editing system can be used for carrying out genetic operations such as efficient knockout, insertion and continuous editing on target genes in escherichia coli and mammalian cells. The invention provides a more convenient and efficient gene editing tool for the research fields of metabolic engineering transformation, gene therapy and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to an ultra-small volume gene editing system based on TnpB protein derived from Campylobacter coli and an application thereof in eukaryotic or prokaryotic genome editing. Background Art

[0002] CRISPR (clustered regularly interspaced short palindromic repeats) is an immune weapon produced by bacteria and viruses in the history of life evolution. Simply put, viruses can integrate their own genes into the genome of bacteria and use the bacterial cell tools to serve their own gene replication. In order to eliminate the foreign invading genes of viruses, bacteria have evolved the CRISPR system. Using this system, bacteria can specifically excise and destroy the viral genome. There are two major types of CRISPR-Cas systems: Class I and Class II. Among them, Class I requires multiple Cas proteins to form a complex to cut the double-stranded DNA, while the Class II CRISPR-Cas system only requires one Cas protein to cut the double-stranded DNA. Because of this feature of the Class II CRISPR-Cas system, it has been widely used in genome editing of prokaryotic and eukaryotic cells after being modified. The CRISPR-Cas9 system consists of two parts: the Cas9 nuclease that cuts the double-stranded DNA and the sgRNA (single guide RNA) with guiding function. In cells, when Cas9 protein and sgRNA coexist and combine to form a complex, sgRNA guides the specific target sequence, where Cas9 protein cuts and produces DNA double strand breaks (DSBs), thereby triggering the intracellular DNA repair mechanism. There are two repair methods in eukaryotes: homologous recombination repair (HDR) and non-homologous DNA endjoining (NHEJ). Heterologous end joining can easily cause random insertions, thereby affecting the function of the target gene and the stability of the genome; although homologous recombination is more accurate than end joining, its homologous recombination repair efficiency in cells is low.

[0003] The emergence of the CRISPR-Cas9 editing system has significantly improved the efficiency of genome editing in organisms. However, when using CRISPR-Cas9 to edit prokaryotes, it is difficult to construct plasmids due to their large size. The biggest difficulty in using CRISPR-Cas9 for treatment is the delivery problem caused by the large size of Cas9. At present, some streamlined versions of the CRISPR-Cas system have appeared, but the efficiency of these systems is generally not as good as the original Cas9 system. Therefore, it is necessary to develop a smaller editing system with high activity.

[0004] TnpB is a transposon-encoded protein belonging to the Ω system. In recent years, studies have found that TnpB is a new type of RNA-guided nuclease with editing activity. Sequence alignment of TnpB and Cas12 proteins shows that the two have similar domains. Bioinformatics analysis speculates that TnpB may be the ancestor of Cas12. Since TnpB is smaller in size than Cas9, it has advantages in cell delivery efficiency and can be used for genome editing and modification in vivo and in vitro. In the future, it can be used as a new type of nucleic acid editing tool in gene therapy, genome modification, trait improvement and other fields. Showing great application prospects. Discovering different types of TnpB proteins will help the application of the enzyme in the field of nucleic acid editing. However, the currently reported TnpB is basically composed of 400 amino acids. The present invention intends to develop a smaller gene editing system based on TnpB. Summary of the invention

[0005] In order to solve the problem of large size of TnpB-based gene editing systems in the prior art, the present invention provides an ultra-small gene editing system based on TnpB (hereinafter referred to as "CcTnpB") protein derived from Campylobacter coli and its application in genome editing of eukaryotes or prokaryotes.

[0006] The technical solution adopted by the present invention is: an ultra-small volume gene editing system, including: a TnpB protein derived from Campylobacter coli or one or more nucleotide sequences encoding the TnpB protein, a ReRNA molecule or one or more nucleic acid molecules encoding the ReRNA molecule, and a guide sequence connected to the ReRNA molecule and complementary to at least a part of the target sequence; the TnpB protein forms a complex with the ReRNA molecule, and edits the target sequence under the guidance of the guide sequence.

[0007] In order to make the editing system smaller, the present invention obtains a protein CcTnpB from Campylobacter coli, which has a molecular weight much smaller than the currently reported TnpB protein, and has only 277 amino acids. It has been verified that the CcTnpB protein can achieve efficient knockout, insertion and continuous editing of the target gene in Escherichia coli, and further experiments show that the CcTnpB protein also has high activity in mammalian cells. Therefore, the CcTnpB protein is expected to provide a simpler, more efficient and more accurate gene editing tool for research fields such as metabolic engineering transformation.

[0008] Specifically, the nucleotide sequence of the TnpB protein is shown in SEQ ID NO.1.

[0009] Specifically, the nucleotide sequence of the ReRNA molecule is shown in SEQ ID NO.2.

[0010] Specifically, the TAM (Transposon Associated Motif) sequence at the 5' end of the target sequence is 5'-TTTAT.

[0011] Specifically, the length of the guide sequence is not less than 13 nt, more preferably 13 to 24 nt, and further preferably 20 nt.

[0012] The TnpB protein forms a complex with the ReRNA molecule, locates to the target sequence through the guide sequence, and cuts its double-stranded DNA. At the same time, when the TnpB protein cuts the double-stranded DNA, it needs the TAM sequence of -TTTAT at the 5' end of the target sequence, so the sequence needs to be located in the downstream region immediately adjacent to the genome -TTTAT sequence.

[0013] The present invention also provides a vector system containing the coding sequence of the ultra-small volume gene editing system. The vector system includes an editing plasmid, a coding sequence of the TnpB protein constructed on the editing plasmid, a ReRNA molecule coding sequence constructed on the editing plasmid, and a guide sequence connected to the ReRNA molecule, and the coding sequence of the TnpB protein and the ReRNA molecule coding sequence can be constructed into the same editing plasmid, or they can be constructed into different editing plasmids respectively. The vector system can also include upstream / downstream homology arm fragments of the target sequence for homologous recombination constructed on the editing plasmid, and / or donor DNA fragments. The vector system containing the coding sequence of the ultra-small volume gene editing system is constructed into a host cell or a cell to be subjected to genome editing.

[0014] The present invention also provides a cell containing the ultra-small volume gene editing system. The cell can be a prokaryotic cell (such as Escherichia coli) or a eukaryotic cell (such as a human HEK293 cell).

[0015] The present invention also provides the application of the ultra-small volume gene editing system in the construction of a cell factory, specifically the application of the ultra-small volume gene editing system in the genome editing of eukaryotes or prokaryotes. Wherein, the genome editing includes gene knockout, gene integration, multi-site continuous editing, and multi-site simultaneous editing. It has been verified that the ultra-small volume gene editing system can achieve efficient knockout, insertion and continuous editing of target genes in Escherichia coli, and further experiments show that the ultra-small volume gene editing system also has high activity in mammalian cells.

[0016] Therefore, the present invention also provides a method for editing the genome of eukaryotic organisms, the method comprising: transfecting the ultra-small volume gene editing system into eukaryotic cells to be subjected to genome editing through a vector to obtain genome-edited transfected cells. Specifically, the eukaryotic organism is a mammal, such as a human, mouse, rabbit, sheep or other mammal. Among them, the coding sequence of the TnpB protein in the ultra-small volume gene editing system is generally codon-optimized according to eukaryotic organisms. Preferably, the coding sequence of the TnpB protein and the coding sequence of the ReRNA molecule in the ultra-small volume gene editing system are respectively constructed into different editing plasmids, and then the different editing plasmids are transfected into eukaryotic cells together to perform genome editing on the eukaryotic cells.

[0017] Beneficial effects of the present invention: The present invention provides an ultra-small volume gene editing system based on CcTnpB protein. The molecular size of CcTnpB protein is only 277 amino acids, which is much smaller than other currently reported Cas proteins and TnpB proteins, and has advantages in cell delivery efficiency. The ultra-small volume gene editing system has verified its editing activity in Escherichia coli, and can efficiently achieve the knockout, insertion and continuous editing of target genes. It also showed high activity when applied to mammalian cells, and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This is the RE sequence alignment of the CcTnpB protein in Example 1 of the present invention.

[0019] Figure 2 This is the knockout editing efficiency mediated by pCcTnpB / pReRNA in Example 2 of the present invention.

[0020] Figure 3 This is the insertion editing efficiency mediated by pCcTnpB / pReRNA in Example 3 of the present invention.

[0021] Figure 4 It is the substitution editing efficiency mediated by pCcTnpB / pReRNA in Example 4 of the present invention.

[0022] Figure 5 It is the efficiency of pCcTnpB / pReRNA-mediated multi-site continuous editing in Example 5 of the present invention.

[0023] Figure 6 This is the efficiency of simultaneous dual-site editing mediated by pCcTnpB / pReRNA in Example 6 of the present invention.

[0024] Figure 7 This is the editing efficiency of pCcTnpB / pReRNA for HEK293T in Example 7 of the present invention.

[0025] Figure 8 Comparison of NAD concentrations between the chassis strain and the control strain in Example 8 of the present invention. DETAILED DESCRIPTION

[0026] The following is an explanation of the embodiments of the present invention by specific specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied by other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that, in the absence of conflict, the features in the following embodiments and embodiments can be combined with each other. In the embodiments of the present invention, the methods used are all conventional methods unless otherwise specified, and the reagents used can be obtained from commercial sources.

[0027] Example 1: Identification of TAM sequences

[0028] Construction of plasmid pCcTnpB: Using primers with sequences shown in sequence 1 and 2 in the following table, a linearized vector was amplified by PCR using pET28a as a template, and then using primers with sequences shown in sequence 3 and 4, a synthetic gene CcTnpB (GenBank: CP017025.1) was used as a template to amplify the target fragment by PCR, and finally the fragment was connected to the linearized pET28a vector by using a one-step cloning method to obtain the plasmid pCcTnpB.

[0029]

[0030] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 55°C annealing for 30 s, 72°C extension for 4 min), 72°C final extension for 10 min, and 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL kanamycin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0031] The downstream nucleotide sequences of different copy sites of CcTnpB were aligned by BLAST to find the right element (RE) of CcTnpB. Figure 1 , and was synthesized by Tsingke Biotechnology Company.

[0032] Construction of plasmid pReRNA: Use primers shown in sequences 1 and 2 in the following table to amplify a linearized vector by PCR using pBAD-DEST49 as a template, then use primers shown in sequences 3 and 4 to amplify the sacB gene from Bacillus subtilis by PCR, and use a one-step cloning method to clone the fragment into the linearized pBAD-DEST49 vector to obtain plasmid pBAD-sacB, then use primers shown in sequences 5 and 6 in the following table to amplify a linearized vector by PCR using pBAD-sacB as a template, use primers shown in sequences 7 and 8 in the following table to amplify a 200nt fragment from the 3' end to the 5' end by PCR using the synthetic gene RE as a template as the guide RNA required for CcTnpB, and use a one-step cloning method to clone the fragment into the linearized pBAD-sacB vector to obtain pReRNA.

[0033]

[0034]

[0035] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0036] Construction of plasmid pCcTnpB-His: Using primers with sequences 1 and 2 in the following table and pCcTnpB as a template, a 6×His Tag was inserted by mutation PCR to obtain pCcTnpB-His.

[0037]

[0038] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL kanamycin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0039] pCcTnpB-His and pReRNA were simultaneously transferred into competent Escherichia coli BL21 (DE3) by chemical transformation and cultured at 37°C for 12 h. Then, clones were picked out and transferred to 10 mL of LB liquid culture medium containing 50 μg / mL ampicillin and kanamycin, and cultured at 37°C, 180 rpm for 10 h. 2% volume was transferred to 100 mL of LB liquid culture medium containing 50 μg / mL ampicillin and kanamycin, and cultured at 37°C, 180 rpm for 2 h. After that, IPTG (final concentration 0.1 mM) was added for induction, and cultured at 37°C, 180 rpm for 12 h.

[0040] The bacterial solution was centrifuged at 8000 rpm and 8°C to collect the cells. 0.4 g of cells were weighed and added to 8 mL of disruption buffer (20 mM Tris-Hcl pH 8.0, 500 mM NaCl, 5 mM mercaptoethanol, 25 mM imidazole, 5% glycerol) for resuspending, ultrasonically disrupted at 150 W for 15 min, and centrifuged at 8000 rpm and 4°C in a low-temperature centrifuge to collect the supernatant.

[0041] The CcTnpB RNP complex was purified using a gravity column pre-packed with Ni-NTA agarose purification resin as follows:

[0042] Step 1: Add 2 mL of ultrapure water and mix thoroughly with the resin. After the ultrapure water has completely dripped, add another 2 mL of ultrapure water and repeat the washing 3 times.

[0043] Step 2: Add 2 mL of LA solution (20 mM Tris-Hcl pH 8.0, 500 mM NaCl, 5 mM mercaptoethanol, 50 mM imidazole, 5% glycerol) to the resin and mix thoroughly to equilibrate the column material. After the resin is completely dripped, add more and repeat the washing for 3 times.

[0044] Step 3: Add the supernatant and the resin and mix thoroughly. Place on ice for 30 minutes. Open the plunger and wait for the supernatant to drip completely before proceeding to the next step.

[0045] Step 4: Slowly add 2 mL of LA solution, add more after it is completely dripped, and repeat the washing 3 times;

[0046] Step 5: Slowly add 2 mL of solution B (20 mM Tris-Hcl pH 8.0, 500 mM NaCl, 5 mM mercaptoethanol, 200 mM imidazole, 5% glycerol), repeat twice, collect the eluate and determine the protein concentration.

[0047] Construction of 5N plasmid: Single oligonucleotide chain Line1 (5'-GAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGNNNNNTTCTCCTTACGCATCTGTGCGGTATTT CACACCGCATATGCTGGATCCTTGACAGCTAGCTCAGTCC-3') was synthesized by Tsingke Biotechnology Co., Ltd. In order to convert Line1 into a double-stranded DNA template and then clone into the vector, a second single-stranded oligonucleotide Line2 (5'-GGACTGAGCTAGCTGTCAAGGATCCAGCATATGCGGTGTGAAATACCGCACAGA TGCGTAAGGAGAA-3') was synthesized by partial complementation with the 3' end of Line1 to form a partial oligonucleotide double strand. Then, the partial double strand was amplified by polymerase using DreamTaq polymerase (Thermo Fisher Scientific) to generate a complete double strand containing the target sequence (TTCTCCTTACGCATCTGTGC), 5 random base pairs and the cleavage site of BamHI restriction endonuclease. The oligonucleotide double strands purified by GeneJET polymerase chain reaction purification kit (Thermo Fisher Science) were digested with BamHI and connected to the BamHI pre-cut pTZ57R / T vector to construct a library. The linear vector pTZ57R / T contains a protruding ddT at the 3' end, and the PCR fragment generated by Dr eamTaq polymerase contains dA at the 3' end. Therefore, one end of the PCR fragment is connected to the vector through the BamHI sticky end, and the other end is connected to the vector through the A / T end. The connected plasmid library is transformed into Escherichia coli DH5α competent cells and coated on LB solid plates. The colonies are resuspended from the plate with LB liquid culture medium, and the resuspended bacterial solution is collected and the plasmid is extracted.

[0048] Two rounds of PCR were performed: In the first round, the primers shown in sequence 1 and 2 in the following table were used to PCR amplify the upstream and downstream of the 5N target sequence. The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 4 μL template, 1 μL DNA polymerase and 15 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 98°C pre-denaturation for 30 s, then 15 cycles (98°C denaturation for 15 s, 58°C annealing for 15 s, 72°C extension for 30 s), and 72°C final extension for 10 min. The purified product was purified using the GeneJET PCR purification kit (Thermo Fisher Scientific). In the second round, the primers of sequence 3 and 4 were used as templates to add the adapter sequence required for illumina sequencing. The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 4 μL template, 1 μL DNA polymerase and 15 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 98 ° C pre-denaturation for 30 s, then 15 cycles (98 ° C denaturation for 10 s, 65 ° C annealing for 15 s, 72 ° C extension for 30 s), 72 ° C final extension for 10 min. The PCR product was purified using the QIAquick PCR purification kit to obtain the purified product. The concentration of the second round of PCR purification products was measured by Hoechst dye fluorescence assay, combined in an equimolar ratio, and the TAM randomness was verified by illumina sequencing on the MiniSeq sequencer using the illumina MiniSeq high-throughput gene sequencing kit.

[0049] Take 1 μg of 5N plasmid and mix it with reaction buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mM CoCl2) and the eluted protein from the above step (final protein concentration 0.5 g / L), and react at 37°C for 30 min to obtain the enzyme cleavage product.

[0050] 3'-dA was added to the digested product by incubation with 2.5U DreamTaq DNA polymerase (Thermo Fisher Scientific) and 0.5μL 10mM dATP at 72°C for 30min, and purified using GeneJET PCR purification kit (ThermoFisher Scientific). 100ng pUCm-T vector was connected with the digested product containing 3'-dA at the same concentration after purification at 22°C in a 25μL reaction volume for 1h (ligation buffer: 40mM Tris-HCl, 10mM MgCl2, 10mM DTT, 0.5mM ATP, 5% (w / v) PEG4000, 0.5U T4 ligase; Thermo Fisher Scientific) to obtain the ligated product. In order to selectively enrich the cleavage product containing TAM sequence, the primers with the sequences shown in sequence 1 and 2 in the following table were used for PCR amplification with the ligated product as template. The product was amplified by Phusion high-fidelity DNA polymerase (Thermo Fisher Scientific) and purified by GeneJET PCR purification kit (Thermo Fisher Scientific). The primers with sequences 3 and 4 in the following table were used as templates to add adapter sequences by PCR, and finally submitted to Tsingke Biotech for FastNGS deep sequencing. The results showed that 98.7% of the 5N enriched fragments were 5'-TTTAT, so this sequence was selected as the TAM for subsequent experiments.

[0051]

[0052] Example 2: Knockout editing in E. coli

[0053] Select 5'-TTTAT on the mazF site of the E. coli genome as the target site of TAM to construct the plasmid pReRNA-N20-mazF:

[0054] Use the primers shown in sequence 1-4 in the following table and use the Escherichia coli BL21 (DE3) genome as a template to amplify the upstream and downstream homology arm fragments of the mazF site by PCR, then use the primers shown in sequences 5 and 6 and use pReRNA as a template to amplify the linearized vector by PCR, and finally use the one-step cloning method to connect the two fragments to the linearized pReRNA vector to obtain the plasmid pReRNA-mazF, and design mutation primers according to the 20nt after 5'-TTTAT of the mazF site of the Escherichia coli BL21 (DE3) genome as shown in sequences 7-8 in the following table, and use pReRNA-mazF as a template to obtain the mutant pReRNA-N20-mazF by PCR.

[0055]

[0056] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0057] The pCcTnpB / pReRNA system knocks out the E. coli mazF gene. The specific steps are as follows:

[0058] Step 1: First, transform pCcTnpB into E. coli BL21 (DE3) to prepare BL21-pCcTnpB competent cells. The specific method is as follows:

[0059] Take 10 μL from the constructed pCcTnpB bacterial preservation tube and streak it on a plate containing 50 μg / mL kanamycin, and culture it at 37°C for 12 hours; take a single colony on the plate and transfer it to 10 mL LB liquid culture medium containing 50 μg / mL kanamycin and culture it at 37°C and 180 rpm for 10 hours; take the above seed liquid and inoculate it into a 100 mL LB liquid culture medium conical flask containing 50 μg / mL kanamycin at an inoculum of 1%, and culture it at 37°C and 180 rpm for 2 hours; take out the conical flask and put it in a pre-prepared ice box, and ice bath it for 15 minutes; take out the conical flask, and divide the cooled bacterial liquid into 50 mL EP tubes that have been sterilized and dried in advance on the clean bench, and ice bath them for 15 minutes. After balancing the 50 mL EP tube on a balance, put it in a low-temperature centrifuge, and centrifuge it for 10 minutes at a temperature of 4°C and a speed of 5000 rpm; after the centrifugation, take out 50 mL from the low-temperature centrifuge EP tube, put it in an ice box, take it out from the clean bench, discard the residual culture medium in the supernatant, add 10mL of pre-sterilized 0.1M CaCl2 solution, resuspend it in an ice bath for 30min; put it in a low-temperature centrifuge, centrifuge it at 4°C and 4000rpm for 10min; after centrifugation, take out the 50mL EP tube from the low-temperature centrifuge, put it in an ice box, take it out from the clean bench, discard the supernatant, add 2mL of pre-sterilized 0.1M CaCl2+15% glycerol solution, and after complete resuspending, divide it into 1.5mL EP tubes sterilized and dried in advance according to 100μL liquid per tube, write the corresponding competent state mark and the time of making competent state, and store it at -80°C for standby use;

[0060] Step 2: Add plasmid pReRNA-N20-mazF to BL21-pCcTnpB competent cells and place on ice for 30 minutes;

[0061] Step 3: Heat shock the competent cells in a 42°C water bath for 90 seconds, add 600 μL of pre-cooled LB liquid medium in a clean bench, place in a shaker, and incubate at 37°C and 180 rpm for 1 hour;

[0062] Step 4: Centrifuge the competent cells obtained in step 3 at 6000rpm for 1min, discard 500μL of supernatant on the clean bench, resuspend and apply to a mixed plate containing 50μg / mL kanamycin + 50μg / mL ampicillin + 0.2g / L arabinose, and culture at 37℃ for 12h. Verify whether the genome is successfully edited by colony PCR at the editing site. The results are as follows: Figure 2 , the number of transformed clones was 2673, and the success rate was 90%.

[0063] Example 3: Insertion editing in E. coli

[0064] The 5'-TTTAT on the lacZ site and purA site of the E. coli genome was selected as the target site of TAM to construct plasmids pReRNA-N20-lacZ and pReRNA-N20-purA:

[0065] Using primers as shown in sequence 1-4 in the following table and using the Escherichia coli BL21 (DE3) genome as a template, PCR was used to amplify the upstream and downstream homology arm fragments of the lacZ site. Then, using primers as shown in sequences 5 and 6, PCR was used to amplify the mCherry fragment. Then, using primers as shown in sequences 7 and 8, PCR was used to amplify the linearized vector using pReRNA as a template. Finally, the three fragments were connected to the linearized pReRNA vector using a one-step cloning method to obtain the plasmid pReRNA-lacZ. According to the 20 nt after 5'-TTTAT of the LacZ site of the Escherichia coli BL21 (DE3) genome, mutation primers were designed as shown in sequences 9-10 in the following table and pReRNA-arcA was used as a template to obtain the mutant pReRNA-N20-lacZ.

[0066]

[0067] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0068] Using primers as shown in sequence 1-4 in the following table and using the Escherichia coli BL21 (DE3) genome as a template, PCR was used to amplify the upstream and downstream homology arm fragments of the purA site. Then, using primers as shown in sequences 5 and 6, PCR was used to amplify the mCherry fragment. Then, using primers as shown in sequences 7 and 8, PCR was used to amplify the linearized vector using pReRNA as a template. Finally, the three fragments were connected to the linearized pReRNA vector using a one-step cloning method to obtain the plasmid pReRNA-purA. Mutation primers were designed according to the 20 nt after 5'-TTTAT of the purA site of the Escherichia coli BL21 (DE3) genome as shown in sequences 9-10 in the following table. Using pReRNA-arcA as a template, PCR was performed to obtain the mutant pReRNA-N20-purA.

[0069]

[0070] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0071] The pCcTnpB / pReRNA system mediates insertion and editing at the lacZ site / purA site of the E. coli genome. The specific steps are as follows:

[0072] Step 1: Add plasmid pReRNA-N20-lacZ / pReRNA-N20-purA to BL21-pCcTnpB competent cells and place on ice for 30 minutes;

[0073] Step 2: Heat shock the competent cells in a 42°C water bath for 90 seconds, add 600 μL of pre-cooled LB liquid medium in a clean bench, place in a shaker, and incubate at 37°C and 180 rpm for 1 hour;

[0074] Step 3: Centrifuge the competent cells obtained in step 3 at 6000rpm for 1min, discard 500μL of supernatant on the clean bench, resuspend and apply to a mixed plate containing 50μg / mL kanamycin + 50μg / mL ampicillin + 0.2g / L arabinose, and culture at 37℃ for 12h. Verify whether the genome is successfully edited by colony PCR at the editing site. The results are as follows: Figure 3 The numbers of transformed clones with insertion editing at the LacZ site and purA site were 1384 and 1579, respectively, with success rates of 90% and 80%.

[0075] Example 4: Substitution editing in E. coli

[0076] The 5'-TTTAT on the arcA site and yohK site of the E. coli genome was selected as the target site of TAM to construct plasmids pReRNA-N20-arcA and pReRNA-N20-yohK:

[0077] Using primers as shown in sequence 1-4 in the following table and using the Escherichia coli BL21 (DE3) genome as a template, PCR was used to amplify the upstream and downstream homology arm fragments of the arcA site. Then, using primers as shown in sequences 5 and 6 and using pET28a as a template, PCR was used to amplify a 30 nt specific fragment. Then, using primers as shown in sequences 7 and 8 and using pReRNA as a template, PCR was used to amplify a linearized vector. Finally, the three fragments were connected to the linearized pReRNA vector using a one-step cloning method to obtain the plasmid pReRNA-arcA. Mutation primers were designed according to the 20 nt after 5'-TTTAT of the arcA site of the Escherichia coli BL21 (DE3) genome as shown in sequences 9-10 in the following table, and PCR was performed using pReRNA-arcA as a template to obtain the mutant pReRNA-N20-arcA.

[0078]

[0079] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0080] Using primers as shown in sequences 1-4 in the following table and the Escherichia coli BL21 (DE3) genome as a template, PCR was used to amplify the upstream and downstream homology arm fragments of the yohK site. Then, using primers as shown in sequences 5 and 6 and pET28a as a template, PCR was used to amplify a 30nt specific fragment. Then, using primers as shown in sequences 7 and 8 and pReRNA as a template, PCR was used to amplify a linearized vector. Finally, the three fragments were connected to the linearized pReRNA vector by a one-step cloning method to obtain the plasmid pReRNA-yohK. Mutation primers were designed according to the 20nt after 5'-TTTAT of the yohK site of the Escherichia coli BL21 (DE3) genome as shown in sequences 9-10 in the following table. Using pReRNA-yohK as a template, PCR was performed to obtain the mutant pReRNA-N20-yohK.

[0081]

[0082] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0083] The pCcTnpB / pReRNA system mediates replacement editing at the arcA site / yohK site in the E. coli genome. The specific steps are as follows:

[0084] Step 1: Add plasmid pReRNA-N20-arcA / pReRNA-N20-yohK to BL21-pCcTnpB competent cells and place on ice for 30 minutes;

[0085] Step 2: Heat shock the competent cells in a 42°C water bath for 90 seconds, add 600 μL of pre-cooled LB liquid medium in a clean bench, place in a shaker, and incubate at 37°C and 180 rpm for 1 hour;

[0086] Step 3: Centrifuge the competent cells obtained in step 3 at 6000rpm for 1min, discard 500μL of supernatant on the clean bench, resuspend and apply to a mixed plate containing 50μg / mL kanamycin + 50μg / mL ampicillin + 0.2g / L arabinose, and culture at 37℃ for 12h. Verify whether the genome is successfully edited by colony PCR at the editing site. The results are as follows: Figure 4 The numbers of transformed clones edited by substitution at the arcA site and yohK site were 2091 and 1913, respectively, with success rates of 90% and 80%.

[0087] Example 5 Continuous Editing in E. coli

[0088] The plasmid pReRNA-N20-mazF / pReRNA-N20-arcA / pReRNA-N20-yohK / pReRNA-N20-lacZ / pReRNA-N20-purA of Example 2-4 was used to continuously edit the lacZ / purA / mazF / arcA / yohK sites in the genome of Escherichia coli BL21 (DE3). The results are as follows: Figure 5 , the specific method is as follows:

[0089] Step 1: Transform the plasmid into BL21-pCcTnpB competent cells and verify whether the genome is successfully edited according to steps 1-3 of Example 3;

[0090] Step 2: Transfer the clone successfully edited in step 1 into 10 mL of LB liquid medium containing 50 μg / mL kanamycin + 20 g / L sucrose and culture at 37°C, 180 rpm for 12 h;

[0091] Step 3: Take 10 μL of the bacterial solution from step 2 into a sterilized and dried EP tube, then add 990 μL of sterile water to dilute, repeat the dilution for a total of 10,000 times, take 30 μL of the diluted bacterial solution and spread it on a plate containing 50 μg / mL kanamycin, and culture at 37°C for 12 h;

[0092] Step 4: Use a sterilized and dried toothpick to take a single colony from the plate cultured for 12 hours in step 3, and use the photocopy method to copy it on a plate containing 50 μg / mL kanamycin and a mixed plate containing 50 μg / mL kanamycin + 50 μg / mL ampicillin. After copying, culture at 37°C for 12 hours;

[0093] Step 5: If there is no growth on the plate containing ampicillin, the plasmid is successfully eliminated. Find the corresponding colony on the plate without ampicillin, take a single colony into 10mL LB liquid culture medium containing 50μg / mL kanamycin and culture it at 37℃, 180rpm for 12h, add it to the bacterial preservation tube with 30% glycerol solution at a volume ratio of 1:1, write the corresponding editing site mark and time, and store it at -80℃ for later use;

[0094] Step 6: Repeat step 1 of Example 2 with the gene-edited bacteria in step 5, write the corresponding competent state mark and the time of making the competent state, and store it at a temperature of -80°C for later use;

[0095] Step 7: Repeat steps 1-6 to continuously edit the lacZ / purA / mazF / arcA / yohK sites in the E. coli BL21 (DE3) genome. Figure 5In the first round of editing of the lacZ site, the number of transformed clones and the success rate were 2215 and 90%, respectively; in the second round of editing of the purA site, the number of transformed clones and the success rate were 2109 and 90%, respectively; in the third round of editing of the mazF site, the number of transformed clones and the success rate were 1983 and 90%, respectively; in the fourth round of editing of the arcA site, the number of transformed clones and the success rate were 2147 and 90%, respectively; in the fifth round of editing of the yohK site, the number of transformed clones and the success rate were 2006 and 80%, respectively.

[0096] Example 6 Simultaneous dual-site editing in E. coli

[0097] The pCcTnpB / pReRNA system mediates simultaneous editing at the yohK site and lacZ site in the E. coli genome. The specific steps are as follows:

[0098] Step 1: Add plasmids pReRNA-N20-yohK and pReRNA-N20-lacZ to BL21-pCcTnpB competent cells at the same time and place on ice for 30 minutes;

[0099] Step 2: Heat shock the competent cells in a 42°C water bath for 90 seconds, add 600 μL of pre-cooled LB liquid medium in a clean bench, place in a shaker, and incubate at 37°C and 180 rpm for 1 hour;

[0100] Step 3: Centrifuge the competent cells obtained in step 2 at 6000rpm for 1min, discard 500μL of supernatant on the clean bench, resuspend and apply to a mixed plate containing 50μg / mL kanamycin + 50μg / mL ampicillin + 0.2g / L arabinose, and culture at 37℃ for 12h. Pick a single colony to verify whether the genome is successfully edited by simultaneous colony PCR for the yohK site and lacZ site. The results are as follows: Figure 6 The number of transformed clones and the success rate of simultaneous editing of the lacZ site and yohK site were 2691 and 70%, respectively.

[0101] Example 7: Gene Editing in HEK293

[0102] HEK293 cells were cultured in DMEM medium containing high glucose, sodium pyruvate, non-essential amino acids, GlutaMAX and supplemented with 10% FBS at 37°C and 5% CO2, and passaged every 3 days. 12h before transfection, cells (1×105) were seeded into 48-well plates. The transfection process was performed using Lipofectamine 2000 at a ratio of 2 μL reagent per microgram of plasmid and Opti-MEM medium per 24 μL volume.

[0103] The human codon-optimized CcTnpB gene containing a nuclear localization signal sequence was synthesized by Tsingke Biotechnology Co., Ltd. The sequence is shown in SEQ ID NO.3, and CcTnpB was cloned between the EcoRⅤ and NotI restriction sites of pcDNA3.1(+). The reRNA scaffold sequence and U6 promoter were synthesized, and the reRNA scaffold sequence and U6 promoter were cloned between the NdeI and PstI restriction sites of the pUC19 vector. The EMX1 and AGBL1 sites in the genome were selected (target sequences are shown in the table below).

[0104]

[0105] The reRNA plasmid was reconstructed with the 20 nt at the right end of the 5'-TTTAT sequence, and the reRNA-EMX1 plasmid was obtained by PCR using the primers shown in sequences 1 and 2 in the following table and the reRNA plasmid as a template. The reRNA-AGBL1 plasmid was then obtained by PCR using the primers shown in sequences 3 and 4 and the reRNA plasmid as a template.

[0106]

[0107] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0108] 300 ng CcTnpB plasmid and 200 ng reRNA-EMX1 plasmid, or 300 ng CcTnpB plasmid and 200 ng reRNA-AGBL1 plasmid, were transfected into HEK293 cells to detect the editing activity of CcTnpB on HEK293. All transfected cells were collected 2 days after transfection, digested with trypsin, washed, resuspended in 100 μL PBS and lysed using 500 μL QuickExtract solution.

[0109] The EMX1 target site fragment was amplified by PCR using the primers shown in sequence 1 and 2 in the following table and the cell lysate as a template, or the AGBL1 target site fragment was amplified by PCR using the primers shown in sequence 3 and 4 and the cell lysate as a template. The fragments were purified using the GeneJET PCR purification kit (Thermo Fisher Scientific).

[0110]

[0111] 3'-dA was added to the purified EMX1 target site fragment and AGBL1 target site fragment by incubating with 2.5U DreamTaq DNA polymerase (Thermo Fisher Scientific) and 0.5μL 10mM dATP at 72°C for 30min, and purified using GeneJET PCR purification kit (Thermo Fisher Scientific). 100ng pUCm-T vector was connected with the purified enzyme digestion product containing 3'-dA at equal concentrations at 22°C in a 25μL reaction volume for 1h (connection buffer: 40mMTris-HCl, 10mM MgCl2, 10mM DTT, 0.5mMATP, 5% (w / v) PEG4000, 0.5U T4 ligase; ThermoFisher Scientific) to obtain EMX1-T and AGBL1-T connection products. The obtained EMX1-T and AGBL1-T ligation products were transformed into E. coli BL21 (DE3) competent cells, ice bathed for 30 minutes, and then placed in a 42°C water bath for heat shock for 90 seconds. 600 μL of pre-cooled LB liquid culture medium was added to the clean bench, and incubated in a shaker at 37°C and 180 rpm for 1 hour. After the incubation, the competent cells were centrifuged at 6000 rpm for 1 minute, and 500 μL of supernatant was discarded on the clean bench and resuspended and coated on a plate containing 50 μg / mL ampicillin, and cultured at 37°C for 12 hours. Then 60 single colonies were picked for EMX1-T and AGBL1-T respectively and transferred to 10 mL of LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C and 180 rpm for 10 hours, and then submitted to Tsingke Biological Company for sequencing to analyze whether there was a base deletion at the targeted cutting site, so as to determine whether genome editing occurred. The results showed that mutations occurred at AGBL1 and EMX1 sites at frequencies of 16.7% and 20%, respectively. Figure 7 ).

[0112] Example 8: Construction of high-yield NAD chassis strain

[0113] Nicotinamide phosphoribosyltransferase (NAMPT), phosphoribosylpyrophosphate synthetase (PRS) and nicotinamide mononucleotide adenylyltransferase (NMNAT) were integrated and expressed into the host Escherichia coli BL21 (DE3) using CcTnpB to construct a high-yield nicotinamide adenine dinucleotide (NAD) chassis strain. Among them, NAMPT is derived from Chitinophagapinensis, and the sequence is shown in SEQ ID NO.4, PRS is derived from Escherichia coli, and the sequence is shown in SEQ ID NO.5, and NMNAT is derived from Komagataellaphaffii, and the sequence is shown in SEQ ID NO.6.

[0114] The 5'-TTTAT at the atpI-gidB site of the E. coli genome was selected as the target site of TAM to construct plasmids: pReRNA-N20-NAMPT, pReRNA-N20-PRS and pReRNA-N20-NMNAT:

[0115] Using the primers shown in sequences 1-4 in the following table and the Escherichia coli BL21 (DE3) genome as a template, PCR was used to amplify the upstream and downstream homology arm fragments of the atpI-gidB site. Then, the primers shown in sequences 5 and 6 were used to amplify the NAMPT fragment by PCR. Then, the primers shown in sequences 7 and 8 were used to amplify the linearized vector by PCR with pReRNA as a template. Finally, the three fragments were connected to the linearized pReRNA vector by using a one-step cloning method to obtain the plasmid pReRNA-NAMPT. Mutation primers were designed according to the 20 nt after 5'-TTTAT of the atpI-gidB site of the Escherichia coli BL21 (DE3) genome as shown in sequences 9-10 in the following table. Using pReRNA-NAMPT as a template, PCR was performed to obtain the mutant pReRNA-N20-NAMPT.

[0116]

[0117]

[0118] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0119] Using primers as shown in sequences 1-4 in the following table and the Escherichia coli BL21 (DE3) genome as a template, PCR was used to amplify the upstream and downstream homology arm fragments of the recA site, and then using primers as shown in sequences 5 and 6, PCR was used to amplify the PRS fragment, and then using primers as shown in sequences 7 and 8, PCR was used to amplify the linearized vector using pReRNA as a template. Finally, the three fragments were connected to the linearized pReRNA vector using a one-step cloning method to obtain the plasmid pReRNA-PRS. Mutation primers were designed according to the 20 nt after 5'-TTTAT of the recA site of the Escherichia coli BL21 (DE3) genome as shown in sequences 9-10 in the following table, and PCR was performed using pReRNA-PRS as a template to obtain the mutant pReRNA-N20-PRS.

[0120]

[0121] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0122] Using primers as shown in sequences 1-4 in the following table and the Escherichia coli BL21 (DE3) genome as a template, PCR was used to amplify the upstream and downstream homology arm fragments of the ybbD-ylbG site. Then, using primers as shown in sequences 5 and 6, PCR was used to amplify the NMNAT fragment. Then, using primers as shown in sequences 7 and 8, PCR was used to amplify the linearized vector using pReRNA as a template. Finally, the three fragments were connected to the linearized pReRNA vector using a one-step cloning method to obtain the plasmid pReRNA-NMNAT. Mutation primers were designed according to the 20 nt after 5'-TTTAT of the ybbD-ylbG site of the Escherichia coli BL21 (DE3) genome as shown in sequences 9-10 in the following table. Using pReRNA-NMNAT as a template, PCR was performed to obtain the mutant pReRNA-N20-NMNAT.

[0123]

[0124] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL ampicillin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0125] The repA fragment was amplified by PCR using the primers shown in sequences 1 and 2 with the thermosensitive plasmid pTH18ks1 as a template, and the linearized vector was amplified by PCR using the primers shown in sequences 3 and 4 with pCcTnpB as a template. Finally, the fragment was ligated to the linearized pCcTnpB vector using a one-step cloning method to obtain the plasmid pCcTnpB-repA.

[0126]

[0127] The specific steps are as follows: PCR reaction system (50 μL): 2 μL forward primer (100 μM), 2 μL reverse primer (100 μM), 25 μL 2×Phanta buffer, 1 μL dNTP mixture (10 mM each), 1 μL template, 1 μL DNA polymerase and 18 μL ultrapure water. The PCR program set according to the Phanta Super-Fidelity DNA polymerase manual is as follows: 95°C pre-denaturation for 5 min, then 30 cycles (95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 3 min), 72°C final extension for 10 min, 12°C insulation. The obtained recombinant plasmid was transferred to Escherichia coli BL21 (DE3) competent cells, and the clones were cultured at 37°C for 12 h. Then the clones were picked out and transferred to 10 mL LB liquid culture medium containing 50 μg / mL kanamycin, and cultured at 37°C, 180 rpm for 10 h, sequenced and identified, and the plasmid was extracted.

[0128] The method for preparing the pCcTnpB-repA competent cell is as shown in step 1 of Example 1.

[0129] The pCcTnpB / pReRNA system mediates the integration and expression of NAMPT, PRS and NMNAT in the E. coli genome. The specific steps are as follows:

[0130] Step 1: Add plasmid pReRNA-N20-NAMPT to BL21-pCcTnpB-repA competent cells and place on ice for 30 minutes;

[0131] Step 2: Heat shock the competent cells in a 42°C water bath for 90 seconds, add 600 μL of pre-cooled LB liquid medium in a clean bench, place in a shaker, and incubate at 37°C and 180 rpm for 1 hour;

[0132] Step 3: Centrifuge the competent cells obtained in step 2 at 6000 rpm for 1 min, discard 500 μL of supernatant on the clean bench, resuspend and apply to a mixed plate containing 50 μg / mL ampicillin + 50 μg / mL kanamycin 0.2 g / L arabinose, culture at 37°C for 12 h, pick a single colony for colony PCR to verify whether the genome is successfully edited;

[0133] Step 4: Transfer the clone successfully edited in step 3 into 10 mL of LB liquid medium containing 50 μg / mL kanamycin + 20 g / L sucrose and culture at 37°C, 180 rpm for 12 h;

[0134] Step 5: Take 10 μL of the bacterial solution from step 4 into a sterilized and dried EP tube, then add 990 μL of sterile water to dilute, repeat the dilution for a total of 10,000 times, take 30 μL of the diluted bacterial solution and spread it on a plate containing 50 μg / mL kanamycin, and culture at 37°C for 12 h;

[0135] Step 6: Use a sterilized and dried toothpick to take a single colony from the plate cultured for 12 hours in step 5, and use the copy printing method to copy it on a plate containing 50 μg / mL kanamycin and a mixed plate containing 50 μg / mL kanamycin + 50 μg / mL ampicillin. After copy printing, culture at 37°C for 12 hours;

[0136] Step 7: If there is no growth on the plate containing ampicillin, the plasmid is successfully eliminated. Find the corresponding colony on the plate without ampicillin, take a single colony into 10mL LB liquid culture medium containing 50μg / mL kanamycin and culture it at 37℃, 180rpm for 12h, add it to the bacterial preservation tube with 30% glycerol solution at a volume ratio of 1:1, write the corresponding editing site mark and time, and store it at -80℃ for later use;

[0137] Step 8: Repeat step 1 of Example 2 with the gene-edited bacteria in step 7, write the corresponding competent state marker and the time of making the competent state, and store it at a temperature of -80°C for later use;

[0138] Step 9: Repeat steps 1-8, and sequentially integrate NAMPT, PRS and NMNAT into the genome of E. coli BL21 (DE3). Take 10 μL of the strain with successful integration of the three enzymes from the bacterial preservation tube and add it to 10 mL LB liquid culture medium and culture it at 30°C and 180 rpm for 12 h.

[0139] Step 10: Take 10 μL of the bacterial solution from step 9 into a sterilized and dried EP tube, then add 990 μL of sterile water to dilute, repeat the dilution for a total of 10,000 times, take 30 μL of the diluted bacterial solution and spread it on an LB solid plate, and culture it at 30°C for 12 h;

[0140] Step 11: Use a sterilized and dried toothpick to take a single colony from the plate cultured for 12 hours in step 10, and use the copy printing method to copy it on a plate containing 50 μg / mL kanamycin and a plate without kanamycin in sequence. After copy printing, culture at 37°C for 12 hours;

[0141] Step 12: If there is no growth on the plate containing kanamycin, the plasmid is successfully eliminated. Find the corresponding colony on the plate without kanamycin, take a single colony into 10mL LB liquid culture medium and culture it at 37℃, 180rpm for 12h, add it to the bacterial preservation tube with 30% glycerol solution in a volume ratio of 1:1 and preserve it at -80℃ for later use.

[0142] Step 13: Take 10 μL of the constructed strain in step 12 and add it to 10 mL LB liquid medium and culture it at 37°C, 180 rpm for 12 h, then inoculate it into 100 mL LB liquid medium at a ratio of 1% and culture it at 37°C, 180 rpm for 2 h, add IPTG (final concentration 0.1 μM), culture it at 28°C, 180 rpm for 12 h, and collect the bacteria by centrifugation at 8000 rpm, 4°C for 10 min;

[0143] Step 14: Resuspend the cells from step 13 in 50 mM PBS buffer (K2HPO4+KH2PO4) to obtain a resuspended solution with a cell concentration of 10 g / L, and add a substrate mixture (30 mM NAM, 1 mM ATP, 100 mM D-ribose, 20 mM polyP and 20 mM Mg 2+ ) was reacted in a water bath at pH 7.5, 37°C, and 600 rpm for 6 h, and the reaction was terminated by adding 0.1 mM phosphoric acid.

[0144] The NAD concentration was detected by Shimadzu 20AT HPLC using an Agilent SB-C18 5μm 4.6*250mm column. The specific procedure was as follows: 1mL of trifluoroacetic acid was weighed and dissolved in 1L of ultrapure water, filtered and ultrasonically degassed for 15min as mobile phase A. At the same time, methanol was filtered and ultrasonically degassed for 15min as mobile phase B. Linear gradient elution was used. The gradient program was shown in the table below. 5μL was injected, the column temperature was 25℃, and the detection wavelength was 260nm. The results are shown in the table below. Figure 8 As shown, the NAD concentration of the control strain was 0.88 mM, and the NAD concentration of the NAMPT-PRS-NMNAT chassis strain was 7.28 mM.

[0145]

[0146]

[0147] The embodiments described above are merely descriptions of preferred implementations of the present invention and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope of the present invention.

Claims

1. Ultra-small volume gene editing system, characterized in that: include: TnpB protein from Campylobacter coli or one or more nucleotide sequences encoding the TnpB protein, ReRNA molecule or one or more nucleic acid molecules encoding the ReRNA molecule, and a guide sequence connected to the ReRNA molecule and complementary to at least a portion of the target sequence; The TnpB protein forms a complex with the ReRNA molecule and edits the target sequence under the guidance of the guide sequence.

2. The ultra-small volume gene editing system according to claim 1, characterized in that: The nucleotide sequence of the TnpB protein is shown in SEQ ID NO.

1.

3. The ultra-small volume gene editing system according to claim 1, characterized in that: The nucleotide sequence of the ReRNA molecule is shown in SEQ ID NO.

2.

4. The ultra-small volume gene editing system according to claim 1, characterized in that: The TAM sequence at the 5' end of the target sequence is 5'-TTTAT.

5. The ultra-small volume gene editing system according to claim 1, characterized in that: The length of the guide sequence is not less than 13 nt.

6. A vector system containing the coding sequence of the ultra-small volume gene editing system according to any one of claims 1 to 5.

7. A cell containing the ultra-small volume gene editing system according to any one of claims 1 to 5.

8. Use of the ultra-small volume gene editing system according to any one of claims 1 to 5 in constructing a cell factory, characterized in that: The application includes: applying the ultra-small volume gene editing system to eukaryotic or prokaryotic genome editing, and the genome editing includes gene knockout, gene integration, multi-site continuous editing, and multi-site simultaneous editing.

9. A method for editing the genome of a eukaryotic organism, characterized in that: The method comprises: transfecting the ultra-small volume gene editing system according to any one of claims 1 to 5 into eukaryotic cells to be subjected to genome editing via a vector to obtain genome-edited transfected cells.

10. The method according to claim 9, characterized in that The eukaryotic organism is a mammal.

Citation Information

Cited By

  • Engineered TNPB nuclease AG-O18-TM65 and application thereof

    CN120505297A

  • Engineered tnpb nucleases ag-o18-tm65 and uses thereof

    CN120505297B